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Abstract Estimating the power for a non-linear mixed-
effects model-based analysis is challenging due to the lack
of a closed form analytic expression. Often, computation-
ally intensive Monte Carlo studies need to be employed to
evaluate the power of a planned experiment. This is
especially time consuming if full power versus sample size
curves are to be obtained. A novel parametric power esti-
mation (PPE) algorithm utilizing the theoretical distribu-
tion of the alternative hypothesis is presented in this work.
The PPE algorithm estimates the unknown non-centrality
parameter in the theoretical distribution from a limited
number of Monte Carlo simulation and estimations. The
estimated parameter linearly scales with study size allow-
ing a quick generation of the full power versus study size
curve. A comparison of the PPE with the classical, purely
Monte Carlo-based power estimation (MCPE) algorithm
for five diverse pharmacometric models showed an excel-
lent agreement between both algorithms, with a low bias of
less than 1.2 % and higher precision for the PPE. The
power extrapolated from a specific study size was in a very
good agreement with power curves obtained with the
MCPE algorithm. PPE represents a promising approach to
accelerate the power calculation for non-linear mixed
effect models.
Keywords Non-linear mixed effect models  Hypothesis
test  Power  Monte Carlo method  NONMEM
Introduction
The calculation of the expected power of an experiment is
a standard procedure often required by funding agencies,
ethics boards or regulatory agencies. For simple statistical
models, these calculations can be quickly performed using
a simple analytic equation. For more complex models,
analytic power calculations are often intractable and time
consuming Monte Carlo methods need to be employed.
This is especially true for non-linear mixed-effects models
(NLMEM) which are frequently used within the paradigm
of model-based drug development [7] due to their ability to
handle the clustered, longitudinal nature of clinical trial
data. In this work we present a new algorithm for power
estimation which reduces computational effort consider-
ably and evaluate its performance.
Power calculations for NLMEM are classically done by
simulating a large number of datasets and re-estimating the
simulated data with the planned analysis model to generate
the distribution of the test statistic. This distribution is then
used to obtain a power estimate. With this procedure, a
large number of replicates is required for a stable estimate
as each replicate contributes only dichotomous information
(i.e., smaller or larger than the test threshold). This process
is especially time-consuming if the procedure is to be
repeated for different study sizes to obtain full power
versus study size curves (power curves).
Existing alternatives to obtain power curves for
NLMEM faster are Monte Carlo Mapped Power (MCMP)
and Fisher information matrix-based power calculation
(FIM-PC). MCMP, introduced by Vong et al. [14] and
recently extended by Kloprogge et al. [6], uses the differ-
ence in the individual log-likelihood values derived from a
large dataset simulated from a full model and subse-
quently re-estimated with the full and reduced models.
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The individual log-likelihood values are sampled and
summed multiple times for each study size, and the power
at a given study size is calculated as the fraction of indi-
vidual log-likelihood sums larger than the critical value.
FIM-PC for NLMEM was described by Retout et al. [11]
and studied further by Ueckert et al. [13], it uses the the-
oretical relationship between the expected information
matrix and the Wald test to compute the power curve.
The method presented in this work estimates an
unknown parameter in the theoretical distribution of the
test statistic under the alternative hypothesis and scales this
estimate to obtain the power at different study sizes. Unlike
MCMP, the algorithm does not require any special prepa-
ration of the dataset nor the calculation of the expected
Fisher information matrix as FIM-PC. The algorithm will
be referred to as parametric power estimation (PPE).
In this paper, we first introduce the PPE algorithm as
well as a bootstrap procedure to evaluate uncertainty in the
power estimate and a diagnostic to validate the underlying
assumptions of the algorithm. Afterwards, we evaluate the
proposed methods for a diverse set of NLMEM, for both
continuous and discrete outcomes. The reference for our
evaluation constitutes the classical, purely Monte Carlo-
based way of estimating power, we will refer to this
algorithm as Monte Carlo power estimation (MCPE).
Finally, we demonstrate the practical use of our algorithm
by applying it to a hypothetical disease progression




Non-linear mixed effect models
Let yi be a vector of ni observations for individual
i (i ¼ 1; . . .;N) and y be the vector of all observations
(y ¼ ðy1; . . .; yNÞT ). It will be assumed that observation
j for individual i can be described through a NLMEM of
the form
yij ¼ f ðtij; h; gi; zijÞ þ eij ð1Þ
when yij is a continuous outcome or, in case yij is discrete,
through
PðyijjgiÞ ¼ hðtij; h; gi; zijÞ ð2Þ
where f and h are non-linear functions, tij is the time of
observation j, h is a vector of fixed effect parameter, gi is a
vector of subject-specific random effect parameter, zij is a
vector of covariates and eij is the residual error random
effect. Both random effects are assumed to follow a normal
distribution with mean 0 and covariance matrix X and R for
gi and eij respectively. Furthermore, let H ¼ ðh;X;RÞT
denote the vector of all unknown parameters.
Hypothesis testing and power
In the framework of NLMEM, a simple two-sided test for a
fixed effect parameter hH can be formalized as
H0 : hH ¼ hH0
H1 : hH 6¼ hH0
ð3Þ
where H0, H1 are the null and alternative hypothesis and
hH0 is the parameter value under the null hypothesis.
In the maximum likelihood (ML) framework, hypothesis
tests are performed using a test statistic tðÞ which depends
on the ML estimate H^. Two tests with different test
statistics are considered in this work: the log-likelihood
ratio (LLR) test and the Wald test. The LLR test evaluates
the evidence for the null hypothesis in the log-likelihood








whereLð:Þ denotes the log-likelihood of the observed data
y at the unrestricted maximum likelihood estimate H^ ¼
ðh^; h^H; X^; R^Þ and the restricted maximum likelihood esti-
mate H^0 ¼ ðh^; h^0H; X^; R^Þ, respectively. Commonly, the
term full model is used to refer to the model estimated
without restriction and the term reduced model to refer to
the one estimated with the restriction hH ¼ hH0.
Rather then on the log-likelihood domain, the Wald test
considers the evidence for the null hypothesis in the








where Varðh^HÞ denotes the variance of h^H which is gen-
erally determined from the inverse of the observed Fisher
information matrix I1ðH^ÞH;H.
Both LLR and Wald test asymptotically follow a chi-
square distribution with k degrees of freedom given that the
null hypothesis is true [3]. Hence, both tests will reject the
null hypothesis if tðH^Þ[ v2k;1a where v2k;1a is the 1 a
quantile of the chi-square distribution with k degrees of
freedom. In this setting, the probability of correctly
rejecting the null hypothesis given a specific alternative
hH ¼ hH is called the power of the test p, i.e.
p ¼ P t H^
 
[ v2k;1ajhH ¼ hH
 
ð6Þ
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The power of a study is dependent on its design N, where N
is the set of all individual designs ni, i.e. N ¼ fn1; . . .; nNg.
In this work, mostly the influence of the number of subjects
N on power will be studied and denoted pðNÞ.
Monte Carlo power estimation
The MCPE algorithm estimates the power of a future trial
by simulating SM datasets according to the planned study
design, subsequently re-estimating the simulated datasets
with the intended analysis model and finally calculating the
test statistic for each replicate. The power estimate is then
the fraction of times the null hypothesis was rejected. The
LLR test is used more frequently for MCPE studies as it
can be numerically challenging and more time consuming
to obtain the observed Fisher information, required by the
Wald test, for each of the replicates.
Power versus study size curves
Estimating the power for different study sizes N is a
common task when planning a trial and can be accom-
plished by applying the MCPE algorithm for a predefined
grid of study sizes fN1; . . .;NKg. The procedure for power
estimation through the LLR test-based MCPE algorithm is
described in Algorithm 1.
Parametric power estimation algorithm
Under the alternative hypothesis H1, LLR and Wald test
statistic asymptotically follow a non-central chi-square
distribution with k degrees of freedom and non-centrality
parameter k given as
k ¼ hH  hH0 2I1H;H ð7Þ
where I1H;H is the entry for hH from the inverse of the
expected Fisher information matrix [3].
The PPE algorithm estimates the unknown non-cen-
trality parameter k from a sample of test statistics using
maximum likelihood estimation. Let fv2ðt; k; kÞ denote the
probability density function of the non-central chi-square
distribution with k degrees of freedom and non-centrality
parameter k, and T a vector of LLR test statistics, then an





log fv2ðt; k; kÞ ð8Þ
Based on k^ the power is estimated as
p^P ¼ 1 Fv2ðv21a;k; k; k^Þ ð9Þ
where Fv2 is the cumulative distribution function of the
non-central v2 distribution and v21a;k is the 1 a quantile
of the chi-square distribution.
Power versus study size curves
The expected information matrix for parameters H and
population design N consisting of Nk subjects with identi-
cal design variables n, is given as Nk times the individual
information matrix IðH; nÞ, i.e.
IðH;NÞ ¼ NkIðH; nÞ ð10Þ
For power curves, generally a reference design Nref is
postulated and replicated to arrive at different study sizes.
Hence, combining Eqs. 10 and 7 yields an expression to
scale the non-centrality parameter kref obtained for Nref
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subjects with population design Nref to any study size Nk.




It should be noted that this equation does not require all
subjects to have the same study design, but only assumes
the reference design Nref (potentially including different
groups, etc.) to be replicated for different study sizes.
Combining Eq. 11 with the algorithm outline in the
previous section yields the PPE algorithm for power curves
which is presented in Algorithm 2.
Bootstrap procedure to evaluate Monte Carlo uncertainty
The precision of the estimates from the PPE algorithm
depend on the number of Monte Carlo samples SP used for
the non-centrality parameter estimation. A practical way of
evaluating this influence is through implementation of a
parametric bootstrap procedure [2].
The bootstrap procedure first estimates kref as outlined
in Algorithm 2. In the second step, B sets Tb of random
numbers, each of size SP, are simulated from the non-
central chi-square distribution with k degrees of freedom
and non-centrality parameter kref . Subsequently, an esti-
mates of k^b is obtained for each Tb. Finally, the 2.5th and
97.5th percentile of all k^b is determined and used to cal-
culate a 95 % power confidence interval according to
Eq. 9.
Bootstrap-based diagnostic
A parametric bootstrap procedure can also provide a
diagnostic to evaluate the validity of the assumptions
underlying the PPE algorithm. The procedure is almost
identical to the one described in the previous paragraph,
but instead of calculating the power for all k^b estimates in
the 95 % confidence interval, these estimates are used to
plot the cumulative distribution function of the corre-
sponding non-central chi-square distributions. The result-
ing 95 % confidence band is overlayed with the empirical
cumulative distribution function (ECDF) of the test statis-
tics in T.
Algorithm evaluation
The PPE algorithm and its extensions (bootstrap procedure
and diagnostic) were evaluated in a simulation study with
different pharmacometric models. The evaluation was
performed by comparing the performance of the PPE
algorithm to the MCPE algorithm for power estimation at a
fixed study size (‘‘Bias and precision of MCPE and PPE
algorithm’’ section) as well as in regards to the generation
of power curves (‘‘PPE algorithm-based power curves’’
section). Additionally, the performance of the bootstrap
procedure was evaluated regarding its ability to correctly
estimate the Monte Carlo uncertainty in the PPE power
estimates (‘‘PPE bootstrap procedure’’ section). Finally, the
sensitivity of the diagnostic with respect to the violation of
assumptions was tested (‘‘PPE diagnostic’’ section). All
evaluations were performed with a confidence level of
95 %.
Evaluation models
The evaluation of the power estimation algorithms was
performed based on a simulation study with five different
pharmacometric models for different response types: (1)
binary, (2) time-to-event (TTE), (3) count, (4) pharma-
cokinetic (PK) and (5) pharmacokinetic/pharmacodynamic
(PKPD). For each model the hypothesis test was performed
for a covariate effect of either a dichotomous covariate zi
(binary, TTE and PKPD model) or a continuous covariate
~zi (count and PK model). The model equations as well as
the parameter values and effect sizes used for this com-
parison are given in Table 1.
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The study design used for the different models in the
simulation study are given in Table 2. For the models with
a dichotomous covariate, it was assumed that half the
subjects in the study had a covariate value of 0 and the
other half a value of 1 (e.g., placebo and treatment group).
For the models with a continuous covariate, a normal
distribution with mean 0 and standard deviation 1 was
assumed for the covariate. The study size N used for the
evaluation was selected to target roughly 80 % power.
Bias and precision of MCPE and PPE algorithm
For all five evaluation models the MCPE and the PPE algo-
rithm were run L ¼ 1000 times with study size N (as speci-
fied inTable 2) using100, 200 and400MonteCarlo replicates
(SM in Algorithm 1 and SP in Algorithm 2). Furthermore, a
reference power value pref was obtained for each model by
running the MCPE algorithm with SM ¼10,000 replicates.
Measures of bias (relative bias) and precision (standard
deviation (SD) and range) were used to summarize the
algorithm performance for each model and Monte Carlo
sample size. The relative bias was calculated as











and the range as





where pref is the reference power, p^x;l the power estimate
obtained with algorithm x (x 2 fM;Pg) and px the arith-





PPE algorithm-based power curves
Theabilityof thePPEalgorithm toobtain full powerversus study
size curves was evaluated by generating 1000 power curves for
all five models based on SP ¼ 400 Monte Carlo samples of
study size N. The median PPE-based power curves were
compared to reference power values obtained using the MCPE
algorithmwith 10,000 replicates at 25, 50, 75, 100 and 125 %of
study sizeN (study sizes were rounded to the next even integer
value). This comparison was performed graphically.
PPE bootstrap procedure
The bootstrap procedure (‘‘Bootstrap procedure to evaluate
MonteCarlo uncertainty’’ section)was evaluated for its ability
to characterize the uncertainty due toMonte Carlo noise in the
PPE power estimates. For this evaluation the coverage of the
bootstrap-based 95 %confidence intervals with 1000 samples
was studies for each of the five evaluation models at study
sizesN using either 100, 200 or 400Monte Carlo samples for
the PPE algorithm. For each model and Monte Carlo sample
size, coverage was calculated as the fraction bootstrap-based
confidence intervals out of 1000 repetitions containing the
reference power value pref (determined as specified in ‘‘Bias
and precision of MCPE and PPE algorithm’’ section).
PPE diagnostic
A formal validation of the bootstrap-based diagnostic
procedure (‘‘Bootstrap-based diagnostic’’ section) is
beyond the scope of this manuscript. However, a quick
evaluation of its diagnostic power was performed by run-
ning the procedure for a scenario representing a violation
of the underlying theoretical assumptions.
For this investigation, the binary example from above
was modified by using hH ¼ 0:1insteadof0:3asbefore1 and
estimating the full model with the constraint 0 hH . This
way the null-hypothesis is on the boundary of the param-
eter space and the assumption of a non-central chi-square
distribution of the LLR test statistic might not hold. For
reference, the diagnostic was also generated without this
assumption violation, i.e. 1\hH\1.
Application example
To illustrate its practical use, the PPE algorithm was
implemented using the R plot template functionality of the
stochastic simulation and estimation (SSE) tool in PsN
version 4.0 and applied to hypothetical example of a phase
II Alzheimer’s disease trial evaluating the relative merits of
a 12, 18 or 24 months long trial.
The disease progression model was taken from the work
of Ito et al. [4, 5] and described the observed disease status
for individual i at time tj through the equation
yij ¼ dpðtjÞ þ pboðtjÞ þ ij ð15Þ
where dp() and pbo() indicate the disease progression and
placebo components described as
dpðtÞ ¼ S0 þ at ð16Þ
and
pboðtÞ ¼ Aðekoff t  ekontÞ ð17Þ
where S0 is the baseline disease status and a the disease
progression rate. In the placebo response model, A is the
1 The violation is more apparent if the alternative hypothesis is close
to the boundary
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placebo amplitude and kon, koff are the rate constants for
the placebo onset and offset, respectively. The parameters
were modeled as follows
S0 ¼ h1 þ g1i




where zi is an indicator variable with 0 in the placebo group
and 1 in the treatment group. The parameter values
h ¼ ð56:4; 4:83;20; 2:77; 1:73ÞT , hH ¼ 0:3, x21 ¼ 14:3,
x22 ¼ 6:1, x1;2 ¼ 1:2 and r2 ¼ 7:9 were used. These
values were in part taken from the publication and partly
chosen arbitrarily [4, 5].
A balanced two arm design with placebo and active
treatment group was assumed for this example. Visits were
scheduled every 6 months for a total study duration of
either 12, 18 or 24 months.
Software
The simulations and estimations for all models in the
algorithm comparison were performed in NONMEM
7.3 [1] with the help of PsN version 4.0 [9]. The statistical
software R version 3.0.2 [10] was used to implement the
PPE algorithm, the source code is given in appendix.
Results
Evaluation
Bias and precision of MCPE and PPE algorithm
Table 3 compares the relative bias of the MCPE and the
PPE-based power at Monte Carlo sample sizes of 100,
200 and 400 for all five evaluation models. Unsurpris-
ingly, as also used when calculating the reference, the
MCPE algorithm displayed no major bias in the power
calculation [biasðpMÞ\0:2%] at any sample size for any
of the five models investigated. The bias for the power
calculated using the PPE algorithm, was slightly larger
and differed between models, but remained small for all
models and Monte Carlo sample sizes. The maximal bias
of 1.1 % was observed for the PK model. With the
exception of the TTE model, the bias for the PPE method
was always positive. Furthermore, bias tended to increase
slightly with an increasing Monte Carlo sample size.
The precision of the two algorithms is compared in
Table 4. For both algorithms, precision is increasing with an
increasingMonte Carlo sample size. At the sameMonte Carlo
sample size, however, the power estimates obtained using the
PPE algorithm were considerably more precise than the
MCPE-based estimates. Judging based on the SD, the PPE
algorithm required roughly half the number of Monte Carlo
samples to achieve the same precision. This finding applied
across models and for all samples sizes investigated.
PPE algorithm-based power curves
A comparison of power versus sample size curves as
obtained with the PPE algorithm and the reference power
for all five models is exhibited in Fig. 1. The figure shows
the median PPE-based power curve from 1000 repetitions
as well as the 95 % confidence band together with the
reference. The agreement between reference and median
PPE-based power is high across the whole power curve and
for all models. Only for the binary and the PK model at the
two smallest reference study sizes (N 60 subjects for
binary and N  10 subjects for PK) a larger deviation is
observed. The largest deviation with 8 % was observed for
the power estimated using the PK model at N ¼ 6, all other
deviation were smaller than 3 %.
PPE bootstrap procedure
The results of the coverage evaluation for the PPE bootstrap
procedure is shown in Fig. 2. The achieved coverage level
for the different models is a reflection of the bias shown in
Table 2 Study design specifications (study size N, number and time
of observations and dose) used for the algorithm comparison
Model N Observations Dose
Binary 110 20 equally spaced between 0 and 1 –
TTE 200 1 between 0 and T ¼ 10 –
Count 160 10 equally spaced between 0 and 1 –
PK 20 9 at 1, 2, 4, 8, 24, 48, 168, 336, 503 150
PKPD 50 3 PK at 0.1, 4, 12 and 3 PD at 4, 6, 12 80
Table 3 Relative bias (%) of power estimates from the Monte Carlo
power estimation (MCPE) and parametric power estimation (PPE)
algorithm for Monte Carlo sample sizes of 100, 200 and 400
100 200 400
MCPE PPE MCPE PPE MCPE PPE
Binary -0.2 -0.2 0.0 0.1 -0.1 0.1
TTE 0.0 -0.8 -0.1 -0.8 0.0 -0.7
Count -0.1 0.4 -0.0 0.5 -0.1 0.5
PK -0.0 1.0 -0.1 1.0 0.0 1.1
PKPD 0.1 0.7 0.1 0.9 -0.0 0.8
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Table 3. For the binary model, with no or minimal bias, the
nominal coverage was achieved, while for all other models,
with a larger bias in Table 3, the coverage was below the
nominal level. The largest deviation from the nominal level
was observed for the PKPD model with a coverage 89 %.
Despite these slight deviations from the nominal cover-
age, the method appears to be sufficiently precise to allow
choosing the number of Monte Carlo samples for the PPE
algorithm.
PPE diagnostic
Figure 3 shows the bootstrap-based diagnostic when the
null hypothesis is forced to be on the boundary of the
parameter space and without this restriction. The former
violates one of the assumptions required to derive the
asymptotic distribution of the test statistic and hence the
basis of the PPE algorithm. The diagnostic clearly indicates
this violation, showing the ECDF of the test statistic out-
side the expected confidence band. In the second panel of
Fig. 3, where the violation is removed, the ECDF of the
test statistic remains within the confidence band.
Application example
For thepreparationof thepower study,first, the full and reduced
version of the disease progression model described in ‘‘Appli-
cation example’’ section were implemented in NONMEM and
saved as dp24m.mod and dp24m_red.mod, respectively
(the r-plots script in PsN uses the convention of a ‘‘_red’’ suffix
in thefilename to identify the reducedmodel). Second, a dataset
with 100 subjects, two groups (treatment and placebo) and
observations at 0, 6, 12, 18 and 24 months was generated in R.
Third, the 18 (dp18m.mod and dp18m_red.mod) and 12
months (dp12m.mod and dp12m_red.mod) full and
reduced models were created by adding an appropriate
IGNORE statement to the 24months version of the model, e.g.
Finally, the necessary steps of data simulation, estimation
with all full and reduced models, running of the PPE
algorithm and plotting were invoked with the PsN com-
mand:
where the -samples=200 argument instructs the soft-
ware to run 200 Monte Carlo samples with 10 parallel runs
(-threads=10). With the -rplots=2 argument, both
power versus study size curves and diagnostic curves are
produced (-rplots=1 would generate the power curves
only).
The resulting power versus study size graph is shown in
Fig. 4, it provides an efficient comparison of the influence
of study size and duration on the power to detect a treat-
ment effect. On the cluster system at hand, the full process
took about 6 min. As a comparison, power curves gener-
ated with the MCPE algorithm using 8 different study sizes
per curve would require about 96 min or 16 times longer (8
points per curve and 2 times the number of samples to
reach the same precision).
Discussion
In this work we proposed and evaluated a novel algorithm
to estimate the power of a future study. The algorithm
estimates the unknown parameter in the theoretical distri-
bution of the test statistic under the alternative hypothesis
to obtain more precise estimates with fewer Monte Carlo
samples. At a fixed study size, the PPE algorithm required
about half as many simulations and estimations to achieve
the same level of precision in the power estimate as a
purely Monte Carlo-based method. Most importantly, the
full power versus study size curve could be obtained from a
set of simulations and estimations at a single study size. In
addition to that, two routines of practical utility were pre-
sented allowing uncertainty evaluation due to Monte Carlo
Table 4 Precision, in terms of
standard deviation (SD) and
range, of power estimates from
the Monte Carlo power
estimation (MCPE) and
parametric power estimation
(PPE) algorithm for Monte
Carlo sample sizes 100, 200 and
400
SD Range
100 200 400 100 200 400
MCPE PPE MCPE PPE MCPE PPE MCPE PPE MCPE PPE MCPE PPE
Binary 4.2 2.9 2.9 2.1 2.1 1.5 28.0 18.0 17.5 13.5 15.0 9.3
TTE 3.9 2.5 2.7 1.8 1.9 1.3 28.0 17.5 16.5 11.4 11.8 8.3
Count 4.3 3.1 3.0 2.2 2.1 1.6 28.0 19.9 19.0 13.2 14.3 10.4
PK 4.1 2.9 2.8 2.0 2.1 1.5 25.0 16.8 17.5 11.9 13.2 10.4
PKPD 3.7 2.3 2.6 1.6 1.8 1.1 25.0 14.7 16.5 12.0 11.0 7.2
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noise as well as an evaluation of the underlying assump-
tions of the algorithm.
The PPE algorithm derives its advantages from addi-
tional assumptions, namely the chi-square distribution and
non-central chi-square distribution of the test statistic under
the null and alternative hypothesis as well as the propor-
tionality of the non-centrality parameter over the whole
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Fig. 1 Power versus sample
size curves from the parametric
power estimation (PPE)
algorithm in comparison with
the reference power. The solid
black line indicates the median
and the gray band represents the
95 % confidence band of the
PPE-based power from 1000
runs of the algorithm using 400
Monte Carlo samples. The
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Fig. 2 Coverage of the 95 %
confidence intervals generated
with the parametric power
estimation (PPE) bootstrap
procedure (shown as black dots)
for different models and with
different Monte Carlo sample
sizes. The dashed lines indicate
the nominal confidence level
and the gray bar the uncertainty
associated with running 1000
repetitions





















Fig. 3 Expected and observed
cumulative probability of the
log-likelihood test statistic used
as a diagnostic for the
parametric power estimation
(PPE) algorithm. The panels
show the diagnostic with and
without violation of an
assumption underlying the
algorithm
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therefore, result in a false power prediction. Potential rea-
sons for violations of the two distributional assumptions
include pathological hypotheses (as studied for the evalu-
ation of the diagnostic), biased estimators, local minima in
the likelihood surface, model misspecifications and
numerical problems [15]. The performance of the PPE
algorithm is therefore expected to be model, study design
and even estimation algorithm dependent. Better perfor-
mance is generally expected for simple models with rich
designs and unbiased, exact-likelihood estimation algo-
rithms. For the models evaluated in this work none of those
factors appeared to be a major problem, nevertheless small
violations might be the cause for the slight bias observed
for all examples. The third assumption of a proportionality
of the non-centrality parameter might be violated when
extrapolating to or from very small study sizes. This is a
probable explanation for the discrepancy between PPE
algorithm and reference power for the PK model at a study
size of 6. Another possible factor is an increased type-I
error for the reference power.
When discussing the bias and discrepancy found for the
PPE algorithm, it is important to note that the magnitude
observed here (\2 %) is of little practical relevance.
Generally, the effect of model and parameter uncertainty
will be of much larger magnitude than the bias introduced
through the additional assumptions of the PPE algorithm. It
is also important to acknowledge that the classical MCPE
algorithm implicitly relies on the same distributional
assumptions when the test statistic is compared to the cut-
off from the v2 distribution (v21a;k). However, while for the
MCPE this assumption can be removed by determining the
distribution under the null hypothesis (type I error correc-
tion), this might not work for the PPE algorithm. Even if
the algorithm can be easily adapted to use a different cutoff
value for the hypothesis test, it appears unlikely for the
alternative hypothesis to follow the theoretical non-central
chi-square distribution when the null hypothesis did not,
but this remains to be investigated.
This investigation focuses on simple, uni-variate
hypotheses involving fixed effect parameters only, the PPE
algorithm, however, extends also to more complex cases.
For multivariate, linear hypotheses, for example, it is suf-
ficient to increase the number of degrees of freedom for the
chi-square distributions (central and non-central) corre-
spondingly. Hypotheses involving variances of random
effect parameters contain some potential theoretical com-
plexities. However, in many practically relevant problems
these do not apply and the PPE algorithm should work
without problems.2 We evaluated this by studying the rel-
ative bias of the PPE algorithm for the Count example with
an additional random effect on the treatment parameter, i.e.
ki ¼ h3 expðgi3 þ ðhH þ gHÞ~ziÞ in Table 1. This scenario
corresponds to hypothesis test with one fixed effect
parameter and one random effect variance (H0 : hH ¼ 0
^x2H ¼ 0). The PPE diagnostic did not show any violation
and the relative bias was with 0.1, 0.2 and 0.3 % (obtained
with 100, 200 and 400 Monte Carlo samples, respectively)
similar to the relative bias of the uni-variate case.
Nonetheless, it is advisable to judge the results of a power
estimation with a complex hypothesis carefully.
This paper also proposes and evaluates the performance
of two bootstrap-based procedures, one to judge the influ-
ence of the Monte Carlo sample size and one for
assumption checking. The former was evaluated by
studying the coverage of the method for the five different
evaluation models at different Monte Carlo sample sizes. In
this evaluation, the procedure did not always show the
nominal coverage with deviations of up to 6 %. Results
should, thus, be interpreted with caution and resulting
confidence intervals be regarded as approximate. Never-
theless, the uncertainty information provides a valuable
addition from a practical perspective allowing a quick
evaluation whether more Monte Carlo samples are
required. The procedure for assumption checking was not
formally evaluated. For the example with the null
hypothesis on the boundary, the procedure clearly indicated
a violation. However, when applied to the other structural
models of the paper (results not shown) the diagnostic
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PPE Power Curves
Fig. 4 Parametric power estimation (PPE) algorithm-based power
versus sample size curves for different study lengths of an
Alzheimer’s disease trial automatically generated by the PsN SSE
script
2 When a hypothesis tests the presence of a random effect, i.e.
essentially H0 : x2 ¼ 0, the null-hypothesis is on the boundary of the
parameter space (as variances can not be negative) and one of the
assumptions used to derive the theoretical distribution of the test
statistic is violated. However, this violation will have minor impact if
the power is studied for a parameter value hH that is not too close to
the boundary.
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in cases where the PPE algorithm performed satisfactorily.
An improvement of the diagnostic procedure is therefore a
potential focus for future work.
Monte Carlo mapped power (MCMP) as described in
the introduction represents an alternative method to obtain
power versus study size curves quickly. The runtime
comparison of MCMP and PPE is not simple, both algo-
rithms are dependent on a number of settings balancing
algorithm speed and precision of the power estimates. A
quick evaluation of the time to generate a power curve for
the binary model resulted in a average time of 15 m 34 s for
the MCMP algorithm and and average time of 23 m 38 s
for the PPE algorithm (without parallelization). This
comparison was performed based on the results presented
by Vong et al. [14] with settings chosen to match the
precision achieved with a 200 sample PPE estimate. In
practice, the choice of different settings or the paral-
lelization of computations can change these results in either
direction. The results are also believed to be model-de-
pendent. A conclusive comparison of both methods’ run-
time should therefore be the focus of a future study.
However, it seems reasonable to assume that both algo-
rithms have runtimes with the same order of magnitude.
The post-processing time, i.e. the sampling for MCMP and
the non-centrality parameter estimation for the PPE, is
significantly faster for the PPE algorithm. The PPE algo-
rithm is also more transparent about potential violations of
the underlying assumptions, as described in the previous
paragraph, provides uncertainty information and does not
require any special inflated data set. Other advantages of
the PPE algorithm are smooth power curves and its gradual
operation where results are available with the very first test
statistic and then continue to improve. The latter allows
users to stop the procedure when a sufficiently precise
estimates have been obtained (not yet implemented in PsN)
or to add samples and increase precision of an earlier run.
Finally, it should be mentioned that both algorithms could
be combined, i.e. one could use MCMP to obtain a few
samples of the test statistic for one study size and then use
the PPE to obtain the full power curve.
Fisher information matrix-based power calculation
(FIM-PC) is clearly the fastest method to obtain power
curve estimates. However, is a purely asymptotic, does not
take the behavior of the estimation algorithm into account
and relies on approximations of the Fisher information
matrix. The calculation of the expected Fisher information
matrix generally requires the implementation of the model
in another software and is challenging for categorical data
NLMEM. Also, the method does not work if the estimation
model is different from the simulation model, such as when
a simpler model is to be used for the analysis of the data.
For the future, a formal comparison between PPE,
MCMP and FIM-PC would be of value. Furthermore, the
PPE algorithm could be extended to be more robust
regarding outliers (i.e. through non-successful runs), sup-
port sampling-based estimation algorithms (e.g., impor-
tance sampling, SAEM) that might lead to negative test
statistics or allow for simulating with parameter
uncertainty.
Conclusions
PPE as a novel algorithm to obtain full power versus
sample size curves was presented and evaluated. The
algorithm is in good agreement with the classical MCPE
algorithm and drastically accelerates the generation of full
power versus sample size curves for NLMEM.
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